MX2020013535A - Tratamiento de cáncer pulmonar de células no pequeñas (nsclc) en etapa iii y mitigación de las condiciones patológicas asociadas con el tratamiento. - Google Patents

Tratamiento de cáncer pulmonar de células no pequeñas (nsclc) en etapa iii y mitigación de las condiciones patológicas asociadas con el tratamiento.

Info

Publication number
MX2020013535A
MX2020013535A MX2020013535A MX2020013535A MX2020013535A MX 2020013535 A MX2020013535 A MX 2020013535A MX 2020013535 A MX2020013535 A MX 2020013535A MX 2020013535 A MX2020013535 A MX 2020013535A MX 2020013535 A MX2020013535 A MX 2020013535A
Authority
MX
Mexico
Prior art keywords
treatment
stage iii
mitigation
conditions associated
pathological conditions
Prior art date
Application number
MX2020013535A
Other languages
English (en)
Inventor
Yan Lan
Isabelle Dussault
Bawab Samer El
Yulia Vugmeyster
Akash Khandelwal
Olaf Christensen
Italia Grenga
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of MX2020013535A publication Critical patent/MX2020013535A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Pulmonology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Esta descripción se refiere generalmente a regímenes de dosis para la inhibición dirigida de TGF-ß con una proteína de fusión bifuncional para su uso en un método para tratar un paciente sin tratamiento previo diagnosticado con cáncer de pulmón de células no pequeñas (NSCLC) en etapa III, y/o para mitigar una condición patológica asociada con quimioterapia y terapia de radiación (cCRT).
MX2020013535A 2018-06-13 2019-06-12 Tratamiento de cáncer pulmonar de células no pequeñas (nsclc) en etapa iii y mitigación de las condiciones patológicas asociadas con el tratamiento. MX2020013535A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862684385P 2018-06-13 2018-06-13
US201962800808P 2019-02-04 2019-02-04
US201962855170P 2019-05-31 2019-05-31
PCT/US2019/036725 WO2019241353A1 (en) 2018-06-13 2019-06-12 Treatment of stage iii nsclc and mitigation of pathological conditions associated with the treatment

Publications (1)

Publication Number Publication Date
MX2020013535A true MX2020013535A (es) 2021-02-26

Family

ID=68843181

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020013535A MX2020013535A (es) 2018-06-13 2019-06-12 Tratamiento de cáncer pulmonar de células no pequeñas (nsclc) en etapa iii y mitigación de las condiciones patológicas asociadas con el tratamiento.

Country Status (14)

Country Link
US (1) US20210113656A1 (es)
EP (1) EP3806842A4 (es)
JP (1) JP2021527083A (es)
KR (1) KR20210020098A (es)
CN (1) CN112566634A (es)
AU (1) AU2019284765A1 (es)
BR (1) BR112020025452A2 (es)
CA (1) CA3103245A1 (es)
CL (1) CL2020003204A1 (es)
IL (1) IL279353A (es)
MX (1) MX2020013535A (es)
SG (1) SG11202012426WA (es)
TW (1) TW202011954A (es)
WO (1) WO2019241353A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021529777A (ja) * 2018-07-02 2021-11-04 メルク パテント ゲーエムベーハー 進行非小細胞肺癌の治療のための標的ＴＧＦ−β阻害による組み合わせ療法
WO2021209458A1 (en) * 2020-04-14 2021-10-21 Ares Trading S.A. Combination treatment of cancer
CN114057877A (zh) * 2020-08-07 2022-02-18 百奥泰生物制药股份有限公司 抗pd-l1抗体及其应用
WO2024052514A1 (en) * 2022-09-09 2024-03-14 Astrazeneca Ab Compositions and methods for treating advanced solid tumors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10202108879SA (en) * 2014-02-10 2021-09-29 Merck Patent Gmbh TARGETED TGFβ INHIBITION
NZ733854A (en) * 2015-02-26 2022-07-01 Merck Patent Gmbh Pd-1 / pd-l1 inhibitors for the treatment of cancer
US20180064662A1 (en) * 2015-03-05 2018-03-08 The General Hospital Corporation Novel compositions and uses of metformin agents
IL264730B1 (en) * 2016-08-12 2024-05-01 Merck Patent Gmbh A pharmaceutical preparation containing TGFbetaRII and another anti-cancer preparation

Also Published As

Publication number Publication date
CN112566634A (zh) 2021-03-26
EP3806842A4 (en) 2022-03-16
TW202011954A (zh) 2020-04-01
BR112020025452A2 (pt) 2021-03-16
JP2021527083A (ja) 2021-10-11
CA3103245A1 (en) 2019-12-19
KR20210020098A (ko) 2021-02-23
SG11202012426WA (en) 2021-01-28
US20210113656A1 (en) 2021-04-22
WO2019241353A1 (en) 2019-12-19
CL2020003204A1 (es) 2021-06-18
AU2019284765A1 (en) 2021-01-07
EP3806842A1 (en) 2021-04-21
IL279353A (en) 2021-01-31

Similar Documents

Publication Publication Date Title
MX2020013535A (es) Tratamiento de cáncer pulmonar de células no pequeñas (nsclc) en etapa iii y mitigación de las condiciones patológicas asociadas con el tratamiento.
MX2020008882A (es) Dosificación para tratamiento con anticuerpos antagonistas anti-tigit y anti-pd-l1.
PH12019501116A1 (en) Compounds with anti-tumor activity against cancer cells bearing egfr or her2 exon 20
PH12020551923A1 (en) Methods and compositions for treating cancer
PH12019502661A1 (en) Articles of manufacture and methods for treatment using adoptive cell therapy
NZ750974A (en) Antibody and checkpoint inhibitor combination therapy
MX2018001802A (es) Metodos para el tratamiento del cancer de pancreas metastasico con el uso de terapias de combinacion que comprenden irinotecan liposomal y oxaliplatino.
MX2023001527A (es) Compuestos con actividad inductora de ferroptosis y metodos de uso de estos.
MX2022008868A (es) Tratamiento del cancer con tg02.
MX2021008605A (es) Arn terapéutico y anticuerpos anti-pd1 para canceres de tumor sólido en estadio avanzado.
MX2022002244A (es) Metodo para identificar respondedores a degradantes de smarca2/4.
MX2019006331A (es) Métodos para tratar el cáncer usando anticuerpos anti-pd-l1 y antiandrógenos.
MX2021001517A (es) Terapia basada en microarn dirigida contra canceres positivos para proteina citosolica de linfocito 1 (lcp-1).
WO2018183817A3 (en) Tumor burden as measured by cell free dna
MX2020001727A (es) Terapia de combinacion.
PH12021551036A1 (en) Anti-liv1 immune cell cancer therapy
WO2018064013A8 (en) METHODS FOR TREATING CANCER WITH BAVITUXIMAB BASED ON LEVELS OF β2-GLYCOPROTEIN 1, AND ASSAYS THEREFOR
MX2021002006A (es) Tratamiento del cancer de mama triple negativo con inhibicion dirigida del factor de crecimiento transformante beta (tgf-b).
MX2018002237A (es) Nuevos biomarcadores y metodos para tratar el cancer.
MX2021002241A (es) Uso de linfocitos infiltrantes de tumor para tratar pacientes con carcinoma de pulmón de células no pequeñas (nsclc) refractario al anticuerpo anti muerte programada 1 (pd-1).
MX2021003214A (es) Metodos terapeuticos y de diagnostico para el cancer de vejiga.
MX2020013103A (es) Metodos de uso de cd24 para la prevencion y tratamiento de recaida de leucemia.
MX2021003262A (es) Metodos de tratamiento.
MX2020008881A (es) Métodos de tratamiento contra el cáncer que comprenden inhibidores de chk1.
MX2022014180A (es) Metodos, terapias y usos para tratar cancer.